Cargando…
Analysis of Local Recurrence Risk in Ductal Carcinoma In Situ and External Validation of the Memorial Sloan Kettering Cancer Center Nomogram
SIMPLE SUMMARY: Adjuvant treatments after breast-conserving surgery (BCS) in ductal carcinoma in situ (DCIS) have shown to reduce the risk of ipsilateral breast tumor relapse (IBTR), but its effect on overall survival remains controversial. Due to this argument, some nomograms tried to select the pa...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136555/ https://www.ncbi.nlm.nih.gov/pubmed/37190320 http://dx.doi.org/10.3390/cancers15082392 |
_version_ | 1785032246957178880 |
---|---|
author | Oses, Gabriela Mension, Eduard Pumarola, Claudia Castillo, Helena Francesc, León Torras, Inés Cebrecos, Isaac Caparrós, Xavier Ganau, Sergi Ubeda, Belén Bargallo, Xavier González, Blanca Sanfeliu, Esther Vidal-Sicart, Sergi Moreno, Reinaldo Muñoz, Montserrat Santamaría, Gorane Mollà, Meritxell |
author_facet | Oses, Gabriela Mension, Eduard Pumarola, Claudia Castillo, Helena Francesc, León Torras, Inés Cebrecos, Isaac Caparrós, Xavier Ganau, Sergi Ubeda, Belén Bargallo, Xavier González, Blanca Sanfeliu, Esther Vidal-Sicart, Sergi Moreno, Reinaldo Muñoz, Montserrat Santamaría, Gorane Mollà, Meritxell |
author_sort | Oses, Gabriela |
collection | PubMed |
description | SIMPLE SUMMARY: Adjuvant treatments after breast-conserving surgery (BCS) in ductal carcinoma in situ (DCIS) have shown to reduce the risk of ipsilateral breast tumor relapse (IBTR), but its effect on overall survival remains controversial. Due to this argument, some nomograms tried to select the patients who may benefit the most to these not free of side-effects adjuvant treatments. In this study, an external validation of the Memorial Sloan Kettering Cancer Center (MSKCC) nomogram was performed not reaching statistical significance in a Spanish cohort of patients. Nonetheless, the expression of estrogen receptors, not included in the MSKCC nomogram, showed potential prediction power for IBTR in the studied population and may be considered in future nomograms. ABSTRACT: Background: Adjuvant radiotherapy and hormonotherapy after breast-conserving surgery (BCS) in ductal carcinoma in situ (DCIS) have been shown to reduce the risk of local recurrence. To predict the risk of ipsilateral breast tumor relapse (IBTR) after BCS, the Memorial Sloan Kettering Cancer Center (MSKCC) developed a nomogram to analyze local recurrence (LR) risk in our cohort and to assess its external validation. Methods: A historical cohort study using data from 296 patients treated for DCIS at the Hospital Clínic of Barcelona was carried out. Patients who had had a mastectomy were excluded from the analysis. Results: The mean age was 58 years (42–75), and the median follow-up time was 10.64 years. The overall local relapse rate was 13.04% (27 patients) during the study period. Actuarial 5- and 10-year IBTR rates were 5.8 and 12.9%, respectively. The external validation of the MSKCC nomogram was performed using a multivariate logistic regression analysis on a total of 207 patients, which did not reach statistical significance in the studied population for predicting LR (p = 0.10). The expression of estrogen receptors was significantly associated with a decreased risk of LR (OR: 0.25; p = 0.004). Conclusions: In our series, the LR rate was 13.4%, which was in accordance with the published series. The MSKCC nomogram did not accurately predict the IBTR in this Spanish cohort of patients treated for DCIS (p = 0.10). |
format | Online Article Text |
id | pubmed-10136555 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101365552023-04-28 Analysis of Local Recurrence Risk in Ductal Carcinoma In Situ and External Validation of the Memorial Sloan Kettering Cancer Center Nomogram Oses, Gabriela Mension, Eduard Pumarola, Claudia Castillo, Helena Francesc, León Torras, Inés Cebrecos, Isaac Caparrós, Xavier Ganau, Sergi Ubeda, Belén Bargallo, Xavier González, Blanca Sanfeliu, Esther Vidal-Sicart, Sergi Moreno, Reinaldo Muñoz, Montserrat Santamaría, Gorane Mollà, Meritxell Cancers (Basel) Article SIMPLE SUMMARY: Adjuvant treatments after breast-conserving surgery (BCS) in ductal carcinoma in situ (DCIS) have shown to reduce the risk of ipsilateral breast tumor relapse (IBTR), but its effect on overall survival remains controversial. Due to this argument, some nomograms tried to select the patients who may benefit the most to these not free of side-effects adjuvant treatments. In this study, an external validation of the Memorial Sloan Kettering Cancer Center (MSKCC) nomogram was performed not reaching statistical significance in a Spanish cohort of patients. Nonetheless, the expression of estrogen receptors, not included in the MSKCC nomogram, showed potential prediction power for IBTR in the studied population and may be considered in future nomograms. ABSTRACT: Background: Adjuvant radiotherapy and hormonotherapy after breast-conserving surgery (BCS) in ductal carcinoma in situ (DCIS) have been shown to reduce the risk of local recurrence. To predict the risk of ipsilateral breast tumor relapse (IBTR) after BCS, the Memorial Sloan Kettering Cancer Center (MSKCC) developed a nomogram to analyze local recurrence (LR) risk in our cohort and to assess its external validation. Methods: A historical cohort study using data from 296 patients treated for DCIS at the Hospital Clínic of Barcelona was carried out. Patients who had had a mastectomy were excluded from the analysis. Results: The mean age was 58 years (42–75), and the median follow-up time was 10.64 years. The overall local relapse rate was 13.04% (27 patients) during the study period. Actuarial 5- and 10-year IBTR rates were 5.8 and 12.9%, respectively. The external validation of the MSKCC nomogram was performed using a multivariate logistic regression analysis on a total of 207 patients, which did not reach statistical significance in the studied population for predicting LR (p = 0.10). The expression of estrogen receptors was significantly associated with a decreased risk of LR (OR: 0.25; p = 0.004). Conclusions: In our series, the LR rate was 13.4%, which was in accordance with the published series. The MSKCC nomogram did not accurately predict the IBTR in this Spanish cohort of patients treated for DCIS (p = 0.10). MDPI 2023-04-21 /pmc/articles/PMC10136555/ /pubmed/37190320 http://dx.doi.org/10.3390/cancers15082392 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Oses, Gabriela Mension, Eduard Pumarola, Claudia Castillo, Helena Francesc, León Torras, Inés Cebrecos, Isaac Caparrós, Xavier Ganau, Sergi Ubeda, Belén Bargallo, Xavier González, Blanca Sanfeliu, Esther Vidal-Sicart, Sergi Moreno, Reinaldo Muñoz, Montserrat Santamaría, Gorane Mollà, Meritxell Analysis of Local Recurrence Risk in Ductal Carcinoma In Situ and External Validation of the Memorial Sloan Kettering Cancer Center Nomogram |
title | Analysis of Local Recurrence Risk in Ductal Carcinoma In Situ and External Validation of the Memorial Sloan Kettering Cancer Center Nomogram |
title_full | Analysis of Local Recurrence Risk in Ductal Carcinoma In Situ and External Validation of the Memorial Sloan Kettering Cancer Center Nomogram |
title_fullStr | Analysis of Local Recurrence Risk in Ductal Carcinoma In Situ and External Validation of the Memorial Sloan Kettering Cancer Center Nomogram |
title_full_unstemmed | Analysis of Local Recurrence Risk in Ductal Carcinoma In Situ and External Validation of the Memorial Sloan Kettering Cancer Center Nomogram |
title_short | Analysis of Local Recurrence Risk in Ductal Carcinoma In Situ and External Validation of the Memorial Sloan Kettering Cancer Center Nomogram |
title_sort | analysis of local recurrence risk in ductal carcinoma in situ and external validation of the memorial sloan kettering cancer center nomogram |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136555/ https://www.ncbi.nlm.nih.gov/pubmed/37190320 http://dx.doi.org/10.3390/cancers15082392 |
work_keys_str_mv | AT osesgabriela analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram AT mensioneduard analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram AT pumarolaclaudia analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram AT castillohelena analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram AT francescleon analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram AT torrasines analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram AT cebrecosisaac analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram AT caparrosxavier analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram AT ganausergi analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram AT ubedabelen analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram AT bargalloxavier analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram AT gonzalezblanca analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram AT sanfeliuesther analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram AT vidalsicartsergi analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram AT morenoreinaldo analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram AT munozmontserrat analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram AT santamariagorane analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram AT mollameritxell analysisoflocalrecurrenceriskinductalcarcinomainsituandexternalvalidationofthememorialsloanketteringcancercenternomogram |